NOVEL FAS RNAi THERAPEUTICS AND USES THEREOF
AssigneeEli Lilly and Company
InventorsPatrick Joseph ANTONELLIS, Seth Andrew BAWEL, Matthew Joseph HAMANG, Theodore Curtis JESSOP, Gregory Lawrence LACKNER, Jibo WANG, Takako WILSON
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the FAS receptor (expressed by the FAS gene), thereby decreasing expression of FAS mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of FAS expression and function, such as autoimmune hepatitis.
Claims44
An RNAi agent for reducing FAS gene expression, wherein the RNAi agent comprises a delivery moiety of Formula I conjugated to R, wherein R is a double stranded RNA (dsRNA) comprising an antisense strand and a sense strand:
- wherein R is conjugated to connection point E of Formula I, optionally via a linker,
- wherein the sense strand and the antisense strand form a duplex region, and
- wherein the antisense strand comprises a region of complementarity to a FAS mRNA target sequence of SEQ ID NO:
- 1, and wherein the sense and antisense strand each optionally comprise one or more modified nucleotides and one or more modified internucleotide linkages.
(canceled)
(canceled)
Dependencies are inferred from the claim text.